The Trial Master File (TMF) plays a critical role in demonstrating that clinical trials are conducted appropriately, with a focus on participant safety, data integrity and regulatory compliance.
The following 25 TMF issues highlight common deficiencies that can lead to adverse findings during regulatory inspections. Recurring or systemic deficiencies can raise broader concerns about trial oversight, documentation integrity and inspection readiness.
- Incomplete or Missing Essential TMF Documents
Critical records such as monitoring visit reports, Investigator Brochures, CVs, consents, regulatory submissions, or Serious Adverse Event documentation are absent from the TMF.
- Untimely Filing of Documents
Documentation uploaded late (e.g., >60 days after generation), undermining the contemporaneous principle.
- Poor Version Control
Multiple or inconsistent document versions without clear history, leading to ambiguity about the approved content.
- Lack of Complete eTMF Audit Trails
Missing or inadequate audit trail information in eTMF systems, compromising traceability of edits and actions.
- Use of Non-Compliant Systems (e.g., File Shares)
Reliance on generic file servers (SharePoint, Dropbox) that lack validated audit trails and secure records management.
- No Defined TMF Structure or Map
Absence of a documented TMF Index/Landscape, leading to inconsistent classification and difficulty in locating documents.
- Poor Metadata Quality
Inconsistent or insufficient metadata tagging impacting searchability and classification.
- Lack of Timely TMF Reconciliation
Failure to reconcile legacy data, outstanding expected documents, and placeholders throughout the trial lifecycle.
- Inadequate TMF Quality Control Checks
No routine Quality Control process in place to identify missing or incorrect filings before inspection.
- Placeholders Not Updated or Removed
Overreliance on Expected Document List placeholders without verification that the actual documents are filed.
- Missing Regulatory Correspondence
Informal regulatory communications, approvals, or responses not documented or filed in the TMF.
- Fragmentation Between Sponsor/CRO TMFs
Documentation scattered between sponsor and Clinical Research Organisation (CRO) systems without proper oversight or central indexing.
- Poor Oversight of CRO-Managed TMFs
Sponsors not conducting periodic quality reviews of CRO maintained TMFs, leading to gaps or compliance drift.
- Inadequate SOPs and Training on TMF Processes
Outdated or absent Standard Operating Procedures, and staff not trained on current TMF expectations and system use.
- Incomplete Delegation Logs/Credentials
Missing or outdated staff qualification and delegation records within the TMF.
- Insufficient Archiving Controls
Inadequate physical or electronic archiving safeguards — inadequate access controls, lack of backup, or no long-term retention strategy.
- Lack of Named Archivist or Assigned Roles
No formally documented role responsible for TMF archiving and preservation.
- IT System Validation and Governance Gaps
TMF or eTMF systems not validated to regulatory requirements (e.g., 21 CFR Part 11), or lacking governance controls.
- Uncontrolled Document Deletions
Systems allowing deletion without trace or quality review, leading to loss of inspection evidence.
- Lack of Certified Copies Process
Unclear or absent procedures for certified copies when migrating documents from source systems.
- Poor Correspondence Filing (Emails & Key Decisions)
Essential emails or decision-making records not captured in the TMF, impeding inspection reconstruction.
- TMF Not Inspection-Ready or Accessible
TMFs presented that are incomplete, difficult to access, or spread across multiple systems, impeding inspectors.
- Missing Source Documentation References
Inadequate linking or lack of documentation demonstrating source data verification.
- Poor Documentation of TMF Governance and Oversight
No clear evidence of ongoing monitoring, Key Performance Indicators, or senior oversight of TMF health.
- Hybrid TMF Issues
Inconsistent structure or missing integration between paper and electronic components.
Addressing these TMF issues proactively can strengthen GCP compliance, improve inspection readiness, and help ensure essential clinical trial documentation is complete, accurate, traceable and readily accessible.